These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 24938203)

  • 21. Progress towards an OMERACT-ILAR guideline for economic evaluations in rheumatology.
    Gabriel SE; Tugwell P; Drummond M
    Ann Rheum Dis; 2002 Apr; 61(4):370-3. PubMed ID: 11874847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic issues with new rheumatologic therapeutics.
    Kavanaugh A
    Curr Opin Rheumatol; 2007 May; 19(3):272-6. PubMed ID: 17414954
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Two-year direct and indirect costs for patients with inflammatory rheumatic joint diseases: data from real-life follow-up of patients in the NOR-DMARD registry.
    Kvamme MK; Lie E; Kvien TK; Kristiansen IS
    Rheumatology (Oxford); 2012 Sep; 51(9):1618-27. PubMed ID: 22539479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Musculoskeletal manifestations, pain, and quality of life in Persian Gulf War veterans referred for rheumatologic evaluation.
    Escalante A; Fischbach M
    J Rheumatol; 1998 Nov; 25(11):2228-35. PubMed ID: 9818669
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The National Data Bank for Rheumatic Diseases (NDB).
    Michaud K
    Clin Exp Rheumatol; 2016; 34(5 Suppl 101):S100-S101. PubMed ID: 27762196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Women and arthritis: burden, impact and prevention programs.
    Hootman JM; Sniezek JE; Helmick CG
    J Womens Health Gend Based Med; 2002 Jun; 11(5):407-16. PubMed ID: 12173574
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pain conditions ranked by healthcare costs for members of a national health plan.
    Pasquale MK; Dufour R; Schaaf D; Reiners AT; Mardekian J; Joshi AV; Patel NC
    Pain Pract; 2014 Feb; 14(2):117-31. PubMed ID: 23601620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Health economics: implications for novel antirheumatic therapies.
    Kavanaugh A
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv65-9. PubMed ID: 16239392
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The burden of rheumatoid arthritis and access to treatment: uptake of new therapies.
    Jönsson B; Kobelt G; Smolen J
    Eur J Health Econ; 2008 Jan; 8 Suppl 2():S61-86. PubMed ID: 18097697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of costs in rheumatic diseases: a literature review.
    Ruof J; Hülsemann JL; Stucki G
    Curr Opin Rheumatol; 1999 Mar; 11(2):104-9. PubMed ID: 10319212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biologic disease-modifying drug treatment patterns and associated costs for patients with rheumatoid Arthritis.
    McBride S; Sarsour K; White LA; Nelson DR; Chawla AJ; Johnston JA
    J Rheumatol; 2011 Oct; 38(10):2141-9. PubMed ID: 21844154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Solutions for off-label therapy].
    Schmidt WA
    Z Rheumatol; 2003; 62(Suppl 2):II54-6. PubMed ID: 14648094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A review of cost-effectiveness evaluations as part of national health technology assessments of biologic DMARDs in the treatment of rheumatoid arthritis.
    Iannazzo S; De Francesco M; Gomez-Ulloa D; Benucci M
    Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):455-68. PubMed ID: 23977974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of fibromyalgia severity on health economic costs: results from a European cross-sectional study.
    Winkelmann A; Perrot S; Schaefer C; Ryan K; Chandran A; Sadosky A; Zlateva G
    Appl Health Econ Health Policy; 2011 Mar; 9(2):125-36. PubMed ID: 21332254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The burden of rheumatoid arthritis and access to treatment: health burden and costs.
    Lundkvist J; Kastäng F; Kobelt G
    Eur J Health Econ; 2008 Jan; 8 Suppl 2():S49-60. PubMed ID: 18157732
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The burden associated with neuropathic pain in Western Europe.
    Langley PC; Van Litsenburg C; Cappelleri JC; Carroll D
    J Med Econ; 2013; 16(1):85-95. PubMed ID: 22970839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Severe chronic pain--the reality of treatment in Europe.
    Varrassi G
    Curr Med Res Opin; 2011 Oct; 27(10):2063-4. PubMed ID: 21929442
    [No Abstract]   [Full Text] [Related]  

  • 38. Catastrophizing and pain in arthritis, fibromyalgia, and other rheumatic diseases.
    Edwards RR; Bingham CO; Bathon J; Haythornthwaite JA
    Arthritis Rheum; 2006 Apr; 55(2):325-32. PubMed ID: 16583384
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identifying and Managing Nociplastic Pain in Individuals With Rheumatic Diseases: A Narrative Review.
    Murphy AE; Minhas D; Clauw DJ; Lee YC
    Arthritis Care Res (Hoboken); 2023 Oct; 75(10):2215-2222. PubMed ID: 36785994
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical comorbidities, treatment patterns, and direct medical costs of patients with osteoarthritis in usual care: a retrospective claims database analysis.
    Gore M; Tai KS; Sadosky A; Leslie D; Stacey BR
    J Med Econ; 2011; 14(4):497-507. PubMed ID: 21682606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.